I recently collaborated with and assisted Suneel Mundle, PhD – Senior Global Medical Affairs Lead, Oncology at J&J’s Janssen Pharmaceuticals – to monitor, annotate and highlight latest peer reviewed literature relevant to MDS. The literature review covered Epidemiology, Diagnosis and Prognosis, and Treatment. It was published in the Fall/Winter 2021 MDS Foundation Newsletter, pages 26-28. Details below:
- Mundle Suneel and Bhagwat Rama, Highlights of Latest Literature in MDS. (Annotated bibliography) MDS Foundation Newsletter (international circulation); 27(2): 26-28, 2021 (http://www.mds-foundation.org/newsletters/)
About MDS (source: MDS Foundation; mds-foundation.org)
Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. MDS is often referred to as a “bone marrow failure disorder”. MDS is primarily a disease of the elderly (most patients are older than age 65), but MDS can affect younger patients as well.
- 12,000 – 20,000 MDS cases are reported in the US each year
- Worldwide an estimated 87,000 new cases occur each year
- Approximately 1 out of 3 patients progress to acute myeloid leukemia (AML)
- For patients who do not receive a bone marrow transplant, the average survival rate for low-risk patients is approximately 6 years, and approximately 5 months for high-risk patients
About MDS Foundation (source: MDS Foundation mds-foundation.org)
The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases.
MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.
The MDS Foundation Newsletter is published two times a year.